Superoxide Dismutase 1 Pathway in Amyotrophic Lateral Sclerosis

Superoxide Dismutase 1 Pathway in Amyotrophic Lateral Sclerosis

[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) is a fatal neurodegenerative disorder characterized by progressive loss of motor neurons. Mutations in the [SOD1 gene](/genes/sod1) (Superoxide Dismutase 1) were the first genetic cause identified in familial ALS, accounting for approximately 12-20% of familial ALS cases. Over 190 SOD1 mutations have been identified, providing critical insights into ALS pathogenesis through toxic gain-of-function mechanisms.

Normal SOD1 Function

Enzyme Activity

SOD1 is a 32 kDa metalloenzyme that catalyzes the dismutation of superoxide radical (O₂⁻) to hydrogen peroxide (H₂O₂) and molecular oxygen:

2 O₂⁻ + 2 H⁺ → H₂O₂ + O₂

This reaction protects cells from oxidative damage caused by reactive oxygen species (ROS).

Structure

SOD1 consists of:

• β-barrel fold: 8 antiparallel β-strands
• Metal binding sites: One Zn²⁺ (structural) + One Cu²⁺ (catalytic)
• Disulfide bond: Cys57-Cys146 (intramolecular)
• Dimer interface: Homodimer formation

Cellular Distribution

• Cytosol (predominant)
• Mitochondrial intermembrane space (partial)
• Nucleus (minor)

SOD1 Mutations in ALS

...

Superoxide Dismutase 1 Pathway in Amyotrophic Lateral Sclerosis

[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) is a fatal neurodegenerative disorder characterized by progressive loss of motor neurons. Mutations in the [SOD1 gene](/genes/sod1) (Superoxide Dismutase 1) were the first genetic cause identified in familial ALS, accounting for approximately 12-20% of familial ALS cases. Over 190 SOD1 mutations have been identified, providing critical insights into ALS pathogenesis through toxic gain-of-function mechanisms.

Normal SOD1 Function

Enzyme Activity

SOD1 is a 32 kDa metalloenzyme that catalyzes the dismutation of superoxide radical (O₂⁻) to hydrogen peroxide (H₂O₂) and molecular oxygen:

2 O₂⁻ + 2 H⁺ → H₂O₂ + O₂

This reaction protects cells from oxidative damage caused by reactive oxygen species (ROS).

Structure

SOD1 consists of:

• β-barrel fold: 8 antiparallel β-strands
• Metal binding sites: One Zn²⁺ (structural) + One Cu²⁺ (catalytic)
• Disulfide bond: Cys57-Cys146 (intramolecular)
• Dimer interface: Homodimer formation

Cellular Distribution

• Cytosol (predominant)
• Mitochondrial intermembrane space (partial)
• Nucleus (minor)

SOD1 Mutations in ALS

Common Mutations

| Mutation | Location | Frequency | Phenotype |
|----------|---------|----------|-----------|
| A4V | N-terminus | ~50% (US) | Aggressive, rapid progression |
| G93A | β-strand 4 | Common | Moderate progression |
| G37R | β-strand 2 | Common | Intermediate |
| H46R | Loop 4 | Asian populations | Slow progression |
| L126Z | C-terminus | Rare | Unknown |

Structure-Function Relationships

Mutations affect:

• Metal binding affinity (Cu/Zn)
• Dimer stability
• Disulfide bond integrity
• Proteolytic resistance

Pathogenic Mechanisms

1. Toxic Gain-of-Function

SOD1 mutations cause disease through loss of dismutase activity-independent mechanisms:

Wild-type SOD1 → Normal dismutase → Cellular protection
↓
Mutant SOD1 → Toxic gain-of-function → Multiple pathogenic pathways

2. Protein Aggregation

Mutant SOD1 forms toxic aggregates through multiple mechanisms:

Increased aggregation propensity: Mutant proteins misfold

Impaired chaperone clearance: [Hsp70](/proteins/hsp70-protein), [Hsp90](/entities/hsp90-protein) overwhelmed

Proteasome dysfunction: Accumulation of misfolded proteins

Inclusion body formation: Aggresomes and aggregates

Mermaid Diagram: SOD1 Aggregation Pathway

3. Mitochondrial Dysfunction

SOD1 mutants cause [mitochondrial](/entities/mitochondria) damage through [@nagai2024]:

• Import interference: Disrupted mitochondrial protein import
• Respiratory chain defects: Complex I and IV dysfunction
• ROS overproduction: Paradoxical increase in [oxidative stress](/mechanisms/oxidative-stress)
• Apoptosis activation: Cytochrome c release

4. Axonal Transport Defects

[Motor neurons](/cell-types/motor-neurons) have long axons requiring efficient transport:

Mutant SOD1 disrupts microtubule-based transport

Impaired vesicle trafficking

Reduced neurotrophic factor delivery

Synaptic dysfunction

5. Glial Cell Dysfunction

Non-cell autonomous toxicity in ALS:

• [Astrocytes](/cell-types/astrocytes): Impaired glutamate uptake (EAAT2 loss)
• [Microglia](/cell-types/microglia): Chronic activation, pro-inflammatory cytokine release
• [Oligodendrocytes](/cell-types/oligodendrocytes): Demyelination, metabolic support failure

6. Endoplasmic Reticulum Stress

Mutant SOD1 accumulation in the [ER](/mechanisms/endoplasmic-reticulum-stress) triggers:

• Unfolded Protein Response (UPR) activation
• CHOP-mediated apoptosis
• Calcium dysregulation
• Autophagy impairment

Selective Motor Neuron Vulnerability

Why Motor Neurons?

Motor neurons are selectively vulnerable due to:

Large cell size: High protein synthesis burden

Long axons: Extreme transport requirements

High metabolic demand: High ROS production

Calcium dysregulation: Excitotoxicity susceptibility

Unique RNA processing: Specialized transport granules

Vulnerability Factors

| Factor | Contribution |
|--------|--------------|
| Size | Protein homeostasis burden |
| Axon length | Transport dependence |
| Calcium handling | Excitotoxicity |
| Mitochondria | Energy demand |
| Neurotrophin dependency | Support dependence |

Therapeutic Approaches

Gene-Targeting Strategies

| Approach | Mechanism | Status |
|----------|-----------|--------|
| [Antisense oligonucleotides](/therapeutics/antisense-oligonucleotides-neurodegeneration) | Knockdown SOD1 | Phase 3 (BIIB067) |
| [CRISPR gene editing](/therapeutics/crispr-gene-editing-neurodegeneration) | Correct mutations | Preclinical |
| RNAi | Silence mutant expression | Preclinical |

Small Molecule Approaches

| Target | Compound | Mechanism |
|--------|----------|-----------|
| Aggregation | [Arimoclomol](/therapeutics/arimoclomol-als) | Hsp90 co-inducer |
| Oxidative stress | [Edaravone](/therapeutics/edaravone-als) | ROS scavenger |
| Glutamate | [Riluzole](/therapeutics/riluzole-als) | Anti-excitotoxic |
| Mitochondria | [Olesoxime](/therapeutics/olesoxime-als) | Mitochondrial stabilizer |

Protein Homeostasis Modulation

• Autophagy enhancers: [Rapamycin](/therapeutics/rapamycin-tauopathy), [trehalose](/therapeutics/trehalose-neurodegeneration)
• Proteasome modulators: Bortezomib (caution)
• Hsp90 inhibitors: Geldanamycin derivatives
• Disaggregation: Hsp104 modulators

Biomarkers and Clinical Trials

Disease Progression Markers

• Neurofilament light chain (NfL): Serum/CSF
• Neurofilament phosphorylated heavy chain (pNfH): CSF
• Mutant SOD1: Specific detection in CSF

Clinical Trials Summary

| Trial | Compound | Outcome |
|-------|----------|---------|
| NCT02623699 | BIIB067 (tofersen) | Primary endpoint missed, but showed benefits |
| NCT00706147 | Arimoclomol | Failed Phase 2/3 |
| NCT01908791 | Edaravone | Approved (IV formulation) |

References

[Rosen DR et al., Mutations in Cu/Zn superoxide dismutase gene in familial amyotrophic lateral sclerosis (1993)](https://pubmed.ncbi.nlm.nih.gov/8367410/)

[Bredesen DE et al., Neurodegenerative diseases: expiring contracts or no new insights? (2000)](https://pubmed.ncbi.nlm.nih.gov/10861808/)

[Bruijn LI et al., Aggregation and motor neuron toxicity in an inducible transgene model of familial ALS (2000)](https://pubmed.ncbi.nlm.nih.gov/10751103/)

[Gandhi S et al., SOD1 mutations in ALS: a systematic review (2022)](https://pubmed.ncbi.nlm.nih.gov/35637652/)

[Nagai M et al., Astrocyte toxicity in SOD1-ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/39503754/)

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [SOD1 Gene](/genes/sod1)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [Protein Aggregation in Neurodegeneration](/mechanisms/protein-aggregation)